<DOC>
	<DOCNO>NCT01554514</DOCNO>
	<brief_summary>Thrombotic thrombocytopenic purpura ( TTP ) disease characterize small blood clot throughout body damage major organ cause death . TTP treat plasma exchange ( also call `` plasmapheresis '' ) . Patients respond initially plasma exchange often help later treatment rituximab . The purpose study see whether combine low dos rituximab plasma exchange help patient get good sooner reduce chance get TTP .</brief_summary>
	<brief_title>Low Dose Rituximab Thrombotic Thrombocytopenic Purpura</brief_title>
	<detailed_description>This pilot safety/efficacy study adjuvant low dose rituximab ( 100 mg/week x 4 dos ) plus standard plasma exchange corticosteroid treatment thrombotic thrombocytopenic purpura ( TTP ) severe ADAMTS13 deficiency . Results study subject compare historical control treat initially plasma exchange corticosteroid . This study propose test hypothesis adjuvant low dose rituximab may decrease incidence composite primary endpoint ( exacerbation refractory disease ) acquire TTP severe ADAMTS13 deficiency . A novel ADAMTS13 assay use identify patient TTP severe ADAMTS13 deficiency enrollment , assess utility ADAMST13 biomarker response therapy prognosis .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age 18 great 2 . Diagnosis suspect thrombotic thrombocytopenic purpura ( TTP ) 1 . Platelet count &lt; 80,000 newly diagnose patient &lt; 120,000 relapsed patient 2 . Microangiopathic hemolytic anemia RBC fragmentation 3 . LDH &gt; 1 x ULN 3 . Subjects receive treatment TTP plasma exchange 4 . Subjects start 5th plasma exchange 5 . Plasma ADAMTS13 activity &lt; 10 % 1 . Treatment TTP within past 2 month 2 . Severe active infection indicate sepsis ( requirement pressor without positive blood culture ) clinical evidence enteric infection E. coli O157 : H7 relate organism 3 . Currently treatment cancer ( subject localize skin carcinoma accept ) 4 . Microangiopathic hemolytic anemia due mechanical heart valve 5 . Severe hypertension , define systolic BP &gt; 180 AND diastolic BP &gt; 120 , papilledema 6 . Organ stem cell transplant 7 . Use calcineurin inhibitor ( sirolimus , tacrolimus , cyclosporin A ) within 6 month prior diagnosis TTP 8 . Disseminated intravascular coagulation define : a. INR &gt; 2.0 ( unrelated anticoagulation , unresponsive Vitamin K ) b. Fibrinogen &lt; 100 mg/dl 9 . Pregnancy 10 . Known congenital TTP . 11 . Rituximab within previous year . 12 . HIV history positive serology 13 . History hepatitis B positive serology HBsAg AntiHBc 14 . Persistent unexplained platelet count 150,000/Î¼L within 3 month current TTP presentation 15 . Hypersensitivities allergies murine and/or humanized antibody 16 . Current participation trial investigational therapy device , central catheter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ADAMTS13</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Thrombotic thrombocytopenic purpura</keyword>
	<keyword>TTP</keyword>
	<keyword>Plasma exchange</keyword>
</DOC>